1.
Respir Res
; 22(1): 277, 2021 Oct 26.
Article
in English
| MEDLINE
| ID: mdl-34702264
ABSTRACT
Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease with mortality driven primarily by respiratory failure. Patients with LAM frequently have respiratory infections, suggestive of a dysregulated microbiome. Here we demonstrate that end-stage LAM patients have a distinct microbiome signature compared to patients with end-stage chronic obstructive pulmonary disease.